ERBB2 and gastric cancer: The completion of the ToGA trial and the approval of trastuzumab have positively affected the survival of patients with HER2-positive GC, as this drug has become the standard first-line treatment for patients with advanced metastatic HER2-positive GC, which has established the precedent for GC-targeted therapy [10].